Does Cosentyx Affect Appetite?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists decreased appetite as an uncommon side effect in clinical trials and post-marketing reports. It occurred in about 1-10% of patients, typically mild and transient, resolving without intervention.[1][2]
Common Side Effects Patients Report
Upper respiratory infections, diarrhea, and nasopharyngitis top the list at 10-20% incidence. Appetite changes rank lower, with no strong causal link in large trials like FUTURE or MEASURE studies, where weight loss (potentially tied to appetite) affected under 5%.[2][3] Patient forums note occasional reports of reduced hunger during initial dosing, but these are anecdotal.
Why Might It Suppress Appetite?
IL-17 inhibition reduces inflammation but can indirectly influence cytokines tied to metabolism and gut signaling. No direct mechanism targets appetite centers like the hypothalamus, unlike some biologics (e.g., GLP-1 agonists). Any effect likely stems from resolving disease symptoms, improving overall energy, or rare GI upset.[4]
What Happens If Appetite Drops?
Monitor for unintended weight loss exceeding 5% body weight in a month; consult a doctor if persistent. It's not a flagged serious adverse event by FDA or EMA, but those with eating disorders or low BMI should discuss risks pre-treatment.[1][5] No evidence of increased appetite as a side effect.
How Does It Compare to Other Biologics?
Unlike TNF inhibitors (Humira, Enbrel), which rarely impact appetite, or IL-23 inhibitors (Tremfya), Cosentyx has slightly higher GI-related reports. Weight gain is more common with some JAK inhibitors than appetite loss here.[3][6]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: ClinicalTrials.gov: NCT01365455 (FUTURE 1)
[4]: PubMed: IL-17 and Metabolic Regulation
[5]: EMA Summary of Product Characteristics
[6]: Drugs.com Side Effects Comparison